Gene Expression during Panobinostat Dosing. Gene Expression during Panobinostat Dosing

A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip Overall design: PBMC's were isolated from EDTA blood tubes by Ficoll separation on the indicated visits. Five million cells were lysed directly in PAX-tubes as recommended by manufacturer. Cell lysate was stored at -80C until RNA extraction was performed